A closer look at the GYM-siRNA platform — from structural design to locoregional delivery.
In-depth platform presentations, pipeline updates, and investor briefings — available exclusively to registered participants.
GYM-siRNA is engineered to deliver tunable modulation of oncogenic transcription factors —
combining structural RNA precision with tumor microenvironment-responsive delivery.
This page contains forward-looking statements regarding preclinical research programs. All platform descriptions reflect proprietary technology subject to pending patent protection. Programs have not received regulatory approval. For investigational use only.
Unlike conventional inhibitors that block a single molecular node, SolRiNA GYM-siRNA operates through a multi-stage pharmacological cascade. Each stage is modeled quantitatively, allowing prediction and optimization of downstream network responses.
The cascade bridges structural RNA engineering with network-level pharmacodynamics — translating a single RNA molecule into a network-level therapeutic effect.
Cancer is a network disease. SolRiNA is built on the principle that durable therapeutic responses require multi-node transcription factor modulation — not single-target inhibition.
This page contains forward-looking statements regarding preclinical research programs. All platform descriptions reflect proprietary technology subject to pending patent protection. Programs have not received regulatory approval. For investigational use only.
Oncogenic transcription networks exhibit complex regulatory dynamics — maintained by positive feedback and multi-node interactions — that allow them to sustain high-activity disease states resistant to single-agent intervention.
Conventional inhibitors that block a single node rarely achieve durable network-level responses. Tumor transcription factor networks adapt through compensatory rewiring, rendering monotherapy transiently effective at best. This is the fundamental problem the SolRiNA platform is designed to address.
By applying tunable RNA-mediated perturbations — calibrated through MERIT-based QSP modeling — the platform aims to produce sustained suppression of oncogenic transcription factor activity with durable pharmacodynamic effect.
The SolRiNA platform integrates RNA structural engineering with QSP modeling to predict and optimize therapeutic response at the molecular and network level. Models describe the full pharmacological cascade — from intracellular RNA exposure and RISC formation to transcription factor modulation and downstream gene silencing.
This computational layer enables rational dose regimen design, prediction of pharmacodynamic response profiles, and system-level simulation of how RNA perturbations propagate through oncogenic transcription factor networks over time.
Boltzmann-weighted conformational ensemble analysis identifies structurally optimal RNA candidates — enabling rational, ACS-guided selection and ranking of therapeutic sequences prior to experimental synthesis.
active programs applying SolRiNA GYM-siRNA to oncogenic transcription circuits across cancer.
This page contains forward-looking statements regarding preclinical research programs. All platform descriptions reflect proprietary technology subject to pending patent protection. Programs have not received regulatory approval. For investigational use only.
| Program | Target Circuit | Indication | Modality | Discovery | Preclinical | IND |
|---|---|---|---|---|---|---|
RBX-101 Central NSCLC | STAT3 | Non-small cell lung cancer | GYM-siRNA | |||
RBX-201 MDM2-Amp Sarcoma | MDM2 · p53 Pathway | DDLPS / Soft tissue sarcoma | GYM-siRNA |
Siheung, S. Korea, April 5, 2026 — Ribonabiologics Inc. today announced its official launch, establishing a strategic focus on the development of next-generation RNA interference (RNAi) therapeutics.
Headquartered in Siheung, South Korea, Ribonabiologics is built on a foundation of advanced RNA engineering and structure-guided design. The company is developing its proprietary SolRiNA™ and GYM-siRNA™ platforms, designed to enhance Argonaute (RISC) loading efficiency and improve intracellular delivery — two of the most critical challenges in RNA therapeutics.
Ribonabiologics' lead programs are focused on solid tumor indications, with an initial emphasis on intratumoral delivery approaches. The company's integrated platform combines computational modeling with precision molecular design to optimize therapeutic performance and safety profiles.
Ribonabiologics is currently advancing its discovery pipeline and is actively seeking strategic partnerships to expand the application of its platform technologies globally.